When mRNA (messenger RNA) vaccines are injected into a patient, tiny lipid vesicles transport mRNA molecules through the body fluids and merge with immune cells, called antigen-presenting cells (APCs). mRNA vaccines work to instruct APCs to manufacture proteins called antigens that evoke an immune response to the threat.
Related CAS Insights
Highlights from the CAS Insights webinar on the pharmaceutical patent landscape
New translational research in immuno-oncology may reach patients who do not respond to current therapies
CAS Insights Report: Unlocking the future of pharmaceutical innovation through patent intelligence.
Gain new perspectives for faster progress directly to your inbox.
